Martin Reck - Concepedia

Author

Martin Reck

Also Known As

Giannis Mountzios, L. Paz-Ares, M Reck, M. M. Reck, M. Reck, MARTIN RECK, Mark A Socinski, Martin Reck, Paul Baas, Reck, M.

626

Publications

52.4K

Citations

H-Index

Concepts

All Affiliations

LungenClinic Grosshansdorf German Center for Lung Research Heidelberg University University Hospital Heidelberg Eli Lilly (United States)

About

Martin Reck is an author at LungenClinic Grosshansdorf specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	103	14.5K
2	Health Sciences	20	36	7.4K
3	Business	1	1	25
4	Engineering	1	1	12
5	Public Health	1	1	150

Martin Reck

205

Publications

42.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, New England Journal of Medicine	2018	3.7K
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, New England Journal of Medicine	2018	3.1K
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabé, New England Journal of Medicine	2019	2.8K
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano, Annals of Oncology MedicineCancer ManagementPulmonary BlastomaOncologyRadiation Oncology	2016	2.6K
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up David Planchard, Sanjay Popat, Keith M. Kerr, Annals of Oncology	2018	2.2K
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Edward S. Kim, Vera Hirsh, Tony Mok, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsBronchial Neoplasm	2008	1.2K
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study Thomas J. Lynch, Igor Bondarenko, Alexander Luft, Journal of Clinical Oncology	2012	1K
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Martin Reck, R. Kaiser, Anders Mellemgaard, The Lancet Oncology OncologyNintedanib Versus DocetaxelLume-lung 1Metronomic TherapyClinical Trials	2014	931
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Martin Reck, Tony Mok, Makoto Nishio, The Lancet Respiratory Medicine Open-label Phase 3MedicinePathologyLiver MetastasesCancer Treatment	2019	919

Page 1